(Adnkronos) - Le persone con psoriasi da moderata a severa hanno ora a disposizione una nuova opzione terapeutica. Si tratta di deucravacitinib, il farmaco first-in-class inibitore della tirosin-chinasi a cui l’Agenzia italiana del farmaco (Aifa) ha approvato la rimborsabilità. Il via libera di Aifa è stato al centro della conferenza stampa organizzata da Bristol Myers Squibb a Roma.
Category
🗞
NewsTranscript
00:00Psoriasis is a chronic and recurrent dermatological disease that affects about 3% of the Italian population, strongly compromising their quality of life.
00:15Of these, a third develops a form from moderate to severe.
00:19The latter have today a new drug at their disposal, whose innovative and selective action mechanism allows them to reach levels of effectiveness and safety lasting over time.
00:30This is Deocravacitinib, the first-in-class inhibitor of Tyrosinkinase 2, admitted to reimbursement by AIFA.
00:39Most of the effective therapies for psoriasis have been injection therapies, monoclonal antibodies, so-called biological drugs.
00:48Finally, a small molecule arrives, which can be taken by mouth once a day, which interferes with the mechanisms that lead to the development of plaques.
01:00And how does it do? It binds to a protein that is inside the cells and which has the task of signaling inflammation.
01:07So, by blocking this protein, it blocks the inflammation signal in the skin of our patients.
01:14So far, the data we have tell us that as long as you take Deocravacitinib, as long as you take this tablet a day, psoriasis remains under control.
01:25Some locations of psoriasis plaques are very shocking from a relational point of view.
01:32Today, it is absolutely necessary that a patient can and must have their own treatment, because this allows them to resume their life, to restart their life in their normality.
01:45In addition to the fact that using drugs that lower the inflammatory burden of the patient,
01:53it can also help in the reduction of associated comorbidities, which very often can compromise the patient's life.
02:02Deocravacitinib, the result of the research of Bristol Myers Squibb, confirms the commitment of the company in immunology.
02:10The data confirm the fact that it is a very active molecule, so much so that we already have data at 4 years old that show both the duration of the important response and the profile of safety, which has shown to be a very well-tolerated molecule.
02:30The research goes on, but it is necessary that patients are informed about the new therapeutic opportunities.
02:36Counting on research is a very important thing for us.
02:41Seeing that research works much more, but the information, which is what the association must do, is also an absolutely important link.
02:50Believe me, there are those who do not know where to go, there are those who do not know the beautiful things that are done for this pathology, which when it is in severe form is a devastating matter.